---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-036435"
form_type: "8-K"
ticker: "SCNI"
cik: "0001611747"
company_name: "Scinai Immunotherapeutics Ltd."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:05:44.809887+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BiondVax receives Nasdaq deficiency notice for minimum equity; deficit of $1.76M vs $2.5M required

## Summary
- Stockholders' deficit of $1.76M as of Dec 31, 2022, below Nasdaq's $2.5M minimum equity requirement.
- Company has until June 15, 2023 to submit a plan to regain compliance with Nasdaq Capital Market.
- If plan accepted, Nasdaq may grant up to 180-day extension; if rejected, company can appeal.
- No immediate effect on trading of ADSs under symbol BVXV.

## SEC filing metadata
- accession: 0001213900-23-036435
- form_type: 8-K
- ticker: SCNI
- cik: 0001611747
- company_name: Scinai Immunotherapeutics Ltd.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1611747/000121390023036435/0001213900-23-036435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1611747/000121390023036435/ea177985-8k_biondvax.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-036435
- JSON: https://secwatch.observer/filing/0001213900-23-036435.json
- Plain text: https://secwatch.observer/filing/0001213900-23-036435.txt

## Key facts
- Listing & Compliance Notices
  Scinai Immunotherapeutics Ltd. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 1, 2023, BiondVax Pharmaceuticals Ltd. (the “ Company ”) received a deficiency letter from the staff of the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “ Stockholders’ Equity Requirement ”). The Company’s Annual Report on Form 10-K for the year ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1611747/000121390023036435/0001213900-23-036435-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.